HAUGEN JANET BRUTSCHEA 4

What Happened

• Janet Haugen, a member of the board of directors of West Pharmaceutical Services, received a grant/award of 46 derivative shares on 2026-06-30. The award is recorded at $359.00 per share for a total value of $16,514. This was an award (code A) as part of director compensation, not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-06-30, 46 shares at $359.00 each (total $16,514).
• Security type: Derivative award (phantom/restricted-type units as noted in footnotes).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Footnotes of note:
  • F1: The filing also reflects 791 restricted stock units and dividend equivalents that will vest in full at the next annual shareholder meeting and will be distributable under the Deferred Compensation Plan for Outside Directors.
  • F2: Phantom stock units awarded are to be settled by delivery of shares upon the reporting person's termination as a director.
• Filing timeliness: Report filed 2026-07-01 for a 2026-06-30 transaction — appears timely (Form 4s are typically due within two business days).

Context

• This was a compensation award to an outside director rather than a market purchase or sale, so it generally reflects routine pay practices for board members rather than a trading signal. Derivative awards (phantom units/RSUs) are commonly settled in shares or cash per plan terms and may vest or be paid out on termination or at specified vesting events.